Claritev 과거 순이익 실적
과거 기준 점검 0/6
Claritev 의 수입은 연평균 -26%의 비율로 감소해 온 반면, Healthcare Services 산업은 연평균 22.9%의 비율로 증가했습니다. 매출은 연평균 3.2%의 비율로 감소해 왔습니다.
핵심 정보
-26.02%
순이익 성장률
-24.22%
주당순이익(EPS) 성장률
| Healthcare Services 산업 성장률 | 1.72% |
| 매출 성장률 | -3.19% |
| 자기자본이익률 | n/a |
| 순이익률 | -29.27% |
| 최근 순이익 업데이트 | 31 Mar 2026 |
최근 과거 실적 업데이트
Recent updates
내러티브 업데이트 • Jun 25
CTEV: New Contracts And Management Changes Will Support Future Upside Potential
Analysts have trimmed their average price target on Claritev to $61, reflecting a reset from prior expectations near $90. The revised target continues to be associated with support from new coverage initiations, recent management efforts, and recent contract wins cited across recent research.내러티브 업데이트 • Jun 11
CTEV: New Contracts And Management Changes Will Drive Future Upside Potential
Claritev's updated analyst price target has moved lower by about $3 to $36.83, as analysts factor in slightly softer revenue growth assumptions, a modestly higher discount rate, and a lower future P/E multiple. This is partly offset by higher projected profit margins and recent Street targets that range from $32 to $61.
내러티브 업데이트 • May 27
CTEV: Early FY26 Contracts And DOJ Probe Will Shape Execution Outlook
Analysts have lifted their Claritev price target to $40 from $21, pointing to stronger early FY26 contract wins and new customer additions as key drivers behind the updated fair value estimate of $22 and a higher future P/E assumption. Analyst Commentary Recent research points to improving sentiment around Claritev, with analysts highlighting early FY26 contract wins of US$44m in annual contract value and six new customer additions as key supports for the higher fair value estimate and revised P/E assumption behind the US$40 price target.내러티브 업데이트 • May 05
CTEV: Volume Resilience And 2026 Buybacks Will Support Future Upside
Claritev's analyst fair value has been revised from $42.75 to $39.80 as analysts factor in slightly lower profit margin assumptions and a small reset in future P/E expectations, in line with recent price target trims from several firms following updated guidance and investment plans. Analyst Commentary Street research on Claritev has shifted toward more conservative assumptions on margin, revenue mix and investment timing, while still highlighting areas where execution could support the current valuation over time.Seeking Alpha • Apr 20
Claritev: Compounding Debt Meets Legacy Business Stabilization (Rating Upgrade)
Summary Claritev is upgraded to 'Hold' after a 32% decline, with the short thesis largely played out. Legacy business revenues are stabilizing, showing 6.2% YoY Q4 growth and accelerating full-year growth, despite margin pressure from regulatory changes. BenInsights' failed pivot is now fully reflected in CTEV’s valuation; any positive developments could act as catalysts. CTEV’s $4.6B debt load and negligible free cash flow keep valuation unattractive, with a 9.2x EV/EBITDA multiple deemed expensive for its risk profile. Read the full article on Seeking Alpha내러티브 업데이트 • Apr 20
CTEV: Entrenched Payer Role And 2026 Buyback Capacity Will Support Upside
Claritev's analyst price target has been reset lower, with the model's fair value estimate moving from $44.75 to $42.75 as analysts factor in reduced formal targets from Citi, Guggenheim, and Wells Fargo, along with updated views on revenue growth, profit margins, and future P/E assumptions. Analyst Commentary Recent Street research on Claritev has coalesced around lower price targets, but the tone is mixed, with analysts highlighting both upside drivers and areas where execution and guidance keep them cautious.내러티브 업데이트 • Apr 05
CTEV: Entrenched Position And Buybacks Will Support Volume Driven Earnings Power
Analysts cut the Claritev price target to $21, with updated models reflecting slightly different revenue growth, profit margin, and future P/E assumptions following recent guidance and sector research. Analyst Commentary Recent Street research on Claritev points to a reset in expectations, with several bearish analysts cutting price targets and highlighting execution and balance sheet risks, even as ratings in the sample remain unchanged.내러티브 업데이트 • Mar 22
CTEV: Entrenched Position And Buybacks Will Support More Sustainable Future Margins
Analysts have reduced the Claritev price target to $21 from $33, reflecting updated expectations for slower revenue growth, slightly lower profit margins, and a lower future P/E multiple, even as they cite solid recent results and continued investment in growth initiatives. Analyst Commentary Recent research updates show a clear reset in expectations for Claritev, with multiple firms cutting price targets while generally maintaining existing ratings.내러티브 업데이트 • Mar 07
CTEV: Entrenched Payer Role And 2026 Guidance Reset Will Support Upside
The analyst price target for Claritev has been reduced from $57.25 to $44.75. Analysts cited lower revenue growth and profit margin assumptions, as well as a revised future P/E expectation following recent price target cuts from multiple firms.내러티브 업데이트 • Feb 21
CTEV: Entrenched Position And Deleveraging Will Support More Sustainable Future Margins
Claritev's analyst price target has been reset lower to $63, down from $80, as analysts factor in a slightly lower future P/E assumption of 9.87x. They also note that the company remains an entrenched vendor with accelerating revenue but elevated leverage that can weigh on valuation.내러티브 업데이트 • Feb 06
CTEV: Entrenched Payer Position And Deleveraging Will Support Future Upside
Analysts have trimmed their fair value estimate for Claritev to $57.25 from $85, citing updated Street price targets in the $33 to $63 range and reduced future P/E assumptions, while also acknowledging steady revenue growth and margin expectations. Analyst Commentary Bullish and cautious views on Claritev are both in play, and that split is driving a wide range of price targets and valuation opinions.내러티브 업데이트 • Jan 23
CTEV: Revenue Recovery And Deleveraging Will Support More Sustainable Future Margins
Narrative Update Opening Analysts have trimmed their fair value estimate for Claritev from $80 to $33, citing a lower Street price target that ranges from $63 at the high end to $33, and a view that stronger revenue growth and steady margins are now balanced by a less premium future P/E and concerns about elevated leverage. Analyst Commentary Recent research updates on Claritev highlight a split view, with some firms still constructive on the long term while taking down price targets and others starting coverage at more neutral levels.분석 기사 • Jan 18
Claritev Corporation (NYSE:CTEV) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough
Unfortunately for some shareholders, the Claritev Corporation ( NYSE:CTEV ) share price has dived 26% in the last...내러티브 업데이트 • Jan 09
CTEV: Best In Class Margins And Deleveraging Efforts Will Support Upside
Analysts have raised their average price target on Claritev to US$74 from US$55, citing confidence in the company's ability to accelerate growth while maintaining strong margins, even as some remain cautious about leverage and valuation. Analyst Commentary Recent research paints a mixed picture around Claritev, with bullish analysts highlighting growth potential and margin strength, while more cautious voices focus on balance sheet risk and how much optimism is already reflected in the share price.내러티브 업데이트 • Dec 25
CTEV: Mid Single Digit Revenue Recovery Will Support Best In Class Margins
Analysts have raised their price target on Claritev from 55 dollars to 80 dollars, citing increased confidence that the company can reaccelerate to mid single digit revenue growth by 2026 while sustaining best in class margins. Analyst Commentary Recent research notes highlight a more constructive stance on Claritev's long term prospects, with the latest upgrade reflecting greater confidence in management's roadmap to restore sustainable growth while preserving strong profitability.내러티브 업데이트 • Dec 11
CTEV: Best-In-Class Margins Will Support Return To Mid-Single-Digit Expansion
Claritev's analyst price target has been raised to $74 from $55, as analysts cite growing confidence that the company can return to mid single digit revenue growth by 2026 while sustaining best in class margins. Analyst Commentary Bullish Takeaways Bullish analysts view the higher $74 target as reflecting renewed confidence in Claritev's ability to reaccelerate revenue growth while preserving margin discipline.내러티브 업데이트 • Nov 27
CTEV: Upgraded Buy Rating Will Drive Growth Momentum and Margin Strength
Analysts have raised Claritev’s price target from $80 to $85, reflecting renewed confidence in the company’s accelerating growth and its ability to maintain strong margins. Analyst Commentary Analyst sentiment around Claritev continues to evolve as the company demonstrates a strong execution track record and new growth initiatives.내러티브 업데이트 • Nov 06
CTEV: Upgraded Buy Rating Will Drive Renewed Momentum Through 2026
Narrative Update on Claritev Analysts have raised Claritev's price target from $55 to $74, citing increased confidence in the company's plan to accelerate growth and maintain industry-leading margins. Analyst Commentary Following the recent upgrade and price target revision, analysts have shared a range of insights on Claritev’s prospects and execution trajectory.분석 기사 • Nov 01
Improved Revenues Required Before Claritev Corporation (NYSE:CTEV) Stock's 35% Jump Looks Justified
Claritev Corporation ( NYSE:CTEV ) shares have continued their recent momentum with a 35% gain in the last month alone...내러티브 업데이트 • Oct 23
Analysts Boost Claritev Valuation Amid Growth Optimism and Strategic Developments
Analysts have raised Claritev's fair value estimate from $70.50 to $80.00. They cite growing confidence in the company's accelerated revenue growth outlook and sustained margins following the recent price target upgrade.분석 기사 • Sep 09
Claritev Corporation's (NYSE:CTEV) Share Price Boosted 27% But Its Business Prospects Need A Lift Too
Despite an already strong run, Claritev Corporation ( NYSE:CTEV ) shares have been powering on, with a gain of 27% in...내러티브 업데이트 • Aug 08
Digital Transformation And AI Adoption Will Drive Global Healthcare Expansion
Claritev’s future P/E has increased markedly while net profit margin has declined, indicating higher valuation despite weaker profitability, yet the consensus price target remains unchanged at $49.50. What's in the News Claritev updated full-year 2025 revenue guidance to flat to +2% versus 2024.분석 기사 • Jul 30
Claritev (NYSE:CTEV) Use Of Debt Could Be Considered Risky
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...분석 기사 • Jul 09
Claritev Corporation's (NYSE:CTEV) Price Is Right But Growth Is Lacking After Shares Rocket 25%
Claritev Corporation ( NYSE:CTEV ) shares have continued their recent momentum with a 25% gain in the last month alone...새로운 내러티브 • May 30
AI And Global Partnerships Will Reshape Personalized Medicine
AI-powered analytics, digital transformation, and global expansions position Claritev to monetize higher-value healthcare solutions and tap into growing, aging populations.분석 기사 • May 15
Claritev Corporation (NYSE:CTEV) Shares Fly 30% But Investors Aren't Buying For Growth
Claritev Corporation ( NYSE:CTEV ) shareholders would be excited to see that the share price has had a great month...분석 기사 • Mar 20
Little Excitement Around Claritev Corporation's (NYSE:CTEV) Revenues As Shares Take 28% Pounding
Claritev Corporation ( NYSE:CTEV ) shares have retraced a considerable 28% in the last month, reversing a fair amount...분석 기사 • Feb 03
There's No Escaping MultiPlan Corporation's (NYSE:MPLN) Muted Revenues Despite A 29% Share Price Rise
MultiPlan Corporation ( NYSE:MPLN ) shares have continued their recent momentum with a 29% gain in the last month...분석 기사 • Dec 20
MultiPlan Corporation (NYSE:MPLN) Stock Catapults 28% Though Its Price And Business Still Lag The Industry
Those holding MultiPlan Corporation ( NYSE:MPLN ) shares would be relieved that the share price has rebounded 28% in...분석 기사 • Dec 13
Here's Why MultiPlan (NYSE:MPLN) Is Weighed Down By Its Debt Load
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...분석 기사 • Oct 20
MultiPlan Corporation (NYSE:MPLN) Shares Fly 55% But Investors Aren't Buying For Growth
MultiPlan Corporation ( NYSE:MPLN ) shareholders are no doubt pleased to see that the share price has bounced 55% in...분석 기사 • Aug 18
MultiPlan Corporation (NYSE:MPLN) Not Doing Enough For Some Investors As Its Shares Slump 40%
To the annoyance of some shareholders, MultiPlan Corporation ( NYSE:MPLN ) shares are down a considerable 40% in the...분석 기사 • Jul 04
Little Excitement Around MultiPlan Corporation's (NYSE:MPLN) Revenues As Shares Take 46% Pounding
Unfortunately for some shareholders, the MultiPlan Corporation ( NYSE:MPLN ) share price has dived 46% in the last...분석 기사 • Jul 02
MultiPlan (NYSE:MPLN) Use Of Debt Could Be Considered Risky
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...매출 및 비용 세부 내역
매출 및 비용 세부 내역
Claritev가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.
순이익 및 매출 추이
| 날짜 | 매출 | 순이익 | 일반관리비 | 연구개발비 |
|---|---|---|---|---|
| 31 Mar 26 | 979 | -287 | 183 | 0 |
| 31 Dec 25 | 965 | -284 | 177 | 0 |
| 30 Sep 25 | 951 | -342 | 176 | 0 |
| 30 Jun 25 | 936 | -663 | 166 | 0 |
| 31 Mar 25 | 927 | -1,177 | 155 | 0 |
| 31 Dec 24 | 931 | -1,646 | 151 | 0 |
| 30 Sep 24 | 943 | -1,539 | 142 | 0 |
| 30 Jun 24 | 955 | -1,172 | 142 | 0 |
| 31 Mar 24 | 959 | -632 | 140 | 0 |
| 31 Dec 23 | 962 | -92 | 135 | 0 |
| 30 Sep 23 | 958 | -710 | 102 | 0 |
| 30 Jun 23 | 966 | -667 | 124 | 0 |
| 31 Mar 23 | 1,018 | -617 | 133 | 0 |
| 31 Dec 22 | 1,080 | -573 | 132 | 0 |
| 30 Sep 22 | 1,137 | 102 | 158 | 0 |
| 30 Jun 22 | 1,175 | 161 | 136 | 0 |
| 31 Mar 22 | 1,161 | 100 | 135 | 0 |
| 31 Dec 21 | 1,118 | 102 | 141 | 0 |
| 30 Sep 21 | 1,075 | -96 | 197 | 0 |
| 30 Jun 21 | 1,010 | -463 | 334 | 0 |
| 31 Mar 21 | 941 | -472 | 330 | 0 |
| 31 Dec 20 | 938 | -521 | 323 | 0 |
| 30 Sep 20 | 929 | -335 | 254 | 0 |
| 30 Jun 20 | 951 | -42 | 104 | 0 |
| 31 Mar 20 | 990 | 11 | 87 | 0 |
| 31 Dec 19 | 983 | 10 | 75 | 0 |
| 31 Dec 18 | 1,041 | 36 | 78 | 0 |
| 31 Dec 17 | 1,067 | 648 | 123 | 0 |
양질의 수익: CTEV 은(는) 현재 수익성이 없습니다.
이익 마진 증가: CTEV는 현재 수익성이 없습니다.
잉여현금흐름 대비 순이익 분석
과거 순이익 성장 분석
수익추이: CTEV은 수익성이 없으며 지난 5년 동안 손실이 연평균 26% 증가했습니다.
성장 가속화: 현재 수익성이 없어 지난 1년간 CTEV의 수익 성장률을 5년 평균과 비교할 수 없습니다.
수익 대 산업: CTEV은 수익성이 없어 지난 해 수익 성장률을 Healthcare Services 업계(4.2%)와 비교하기 어렵습니다.
자기자본이익률
높은 ROE: CTEV의 부채가 자산을 초과하여 자본 수익률을 계산하기 어렵습니다.
총자산이익률
투하자본수익률
우수한 과거 실적 기업을 찾아보세요
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/07/04 03:26 |
| 종가 | 2026/07/02 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Claritev Corporation는 9명의 분석가가 다루고 있습니다. 이 중 5명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Steven Valiquette | Barclays |
| Glen Santangelo | Barclays |
| Andrew D'Silva | B. Riley Securities, Inc. |